Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1757
Peer-review started: May 5, 2022
First decision: June 8, 2022
Revised: June 17, 2022
Accepted: September 8, 2022
Article in press: September 8, 2022
Published online: September 27, 2022
There is a nationwide shortage of organs available for liver transplantation. Living donors help meet this growing demand. Not uncommonly, donors will have posi
To analyze the significance of positive autoantibodies in donors on post-tran
We performed a retrospective review of living liver donors who had undergone liver transplantation between January 1, 2012 and August 31, 2021. Demographic characteristics and pre-transplant data including antinuclear antibodies (ANA) and anti-smooth muscle antibody titers were collected in donors. Outcomes of interest were post-transplantation complications including mortality, biliary stri
172 living donor liver transplantations were performed during the study period, of which 115 patients met inclusion criteria. 37 (32%) living donors were auto
Isolated pre-transplant autoantibody positivity is not correlated to worse post-transplant outcomes in living liver donor transplants.
Core Tip: This was a retrospective study designed to analyze the significance of positive autoantibodies in donors on post-transplant outcomes in recipients in living donor liver transplantations. Post-transplantation rates of complications including mortality (P value = 1), infections (P value = 0.66), anastomotic strictures (P value = 0.07), and rejection (P value = 0.30) were found not to be statistically significant between the autoantibody positive and negative groups. These results suggest that isolated pre-transplant autoantibody positivity is not correlated to worse post-transplant outcomes in living liver donor transplants and should not preclude donors from donating.